Affimed Stock (NASDAQ:AFMD), Trade Ideas

Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFMD

AISP

APEI

BASE

BIAF

BYSI

CERS

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

GRFS

HIPO

HSCS

IFBD

INFN

JAGX

LTRN

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

SOPH

TTEC

UNFI

VINC

XRTX

Shares of  United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

ABVC

AREN

ATNF

BRFS

BROG

CALM

FWBI

HALL

JFBR

Kintara Therapeutics, Inc. - Common Stock

KTRA

NEXI

SCYX

Shares of  Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter.

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

ACXP

ADCT

ASTR

BEST

BHIL

CAUD

CREV

DBGI

MGRX

MNPR

RIBT

SNSE

WRNT

Gainers


	Carbon Revolution Public Limited  (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.


Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Affimed NV

Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology

WIIM

Affirmed shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $10.

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight and lowers the price target from $30 to $25.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Affimed, Lowers Price Target to $25

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Affimed

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and raises the price target from $5 to $10.

HC Wainwright & Co. Maintains Buy on Affimed, Raises Price Target to $10

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.67) by 10.18 percent. This is a 31.82 percent increase over losses of $(2.20) per share from the same period last year. The company reported quarterly sales of $444.55 thousand which missed the analyst consensus estimate of $1.70 million by 73.85 percent. This is a 96.10 percent decrease over sales of $11.39 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Affimed Q4 EPS $(1.50) Beats $(1.67) Estimate, Sales $444.55K Miss $1.70M Estimate

Affimed FY2023 EPS €(7.09) Down From €(6.04) YoY, Sales €8.91M Down From €41.35M YoY; Cash, Cash Equivalents And Investments Of €72M Provide Cash Runway Into 2H 2025

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Affimed will report an earnings per share (EPS) of $-1.68. 
Affimed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.30, which was followed by a 19.69% increase in the share price the next day.
Here's a look at Affimed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2</td>
<td>-2.1</td>
<td>-2.1</td>
<td>-2.1</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.7</td>
<td>-2.2</td>
<td>-2.2</td>
<td>-2.2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>20.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711551664_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Affimed were trading at $5.32 as of March 26. Over the last 52-week period, shares are down 25.35%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AFMD/earnings">To track all earnings releases for Affimed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Affimed's Earnings

Affimed N.V. Shares Resume Trade

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Shares of United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) fell sharply during Wednesday&rsquo;s session following <a href="https://www.benzinga.com/quote/UNFI/earnings">second-quarter results.</a>
United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company&rsquo;s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer.
United Natural Foods shares dipped 15.2% to $12.61 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line.</li>
<li>Aptorum Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apm#NASDAQ">APM</a>) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business.</li>
<li>NKGen Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkgn#NASDAQ">NKGN</a>) gained 46.5% to $1.35.</li>
<li>TRxADE HEALTH, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meds#NASDAQ">MEDS</a>) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share.</li>
<li>Airship AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aisp#NASDAQ">AISP</a>) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.</li>
<li>Enviva Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eva#NYSE">EVA</a>) rose 33% to $0.9854 after gaining 42% on Tuesday.</li>
<li>American Public Education, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apei#NASDAQ">APEI</a>) gained 31.8% to $14.99 following upbeat quarterly results.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements.</li>
<li>Cemtrex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cetx#NASDAQ">CETX</a>) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature.</li>
<li>Wave Life Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wve#NYSE">WVE</a>) gained 28.5% to $6.16 following upbeat quarterly results.</li>
<li>Vincerx Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vinc#NASDAQ">VINC</a>) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) rose 24.2% to $5.85.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) gained 23.8% to $14.72.</li>
<li>Lantern Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ltrn#NASDAQ">LTRN</a>) gained 22.6% to $5.90.</li>
<li>Energem Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/encp#NASDAQ">ENCP</a>) rose 22.4% to $8.31. Energem&rsquo;s merger partner recently said it accelerated the timeline for its planned manufacturing plant in Malaysia.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) gained 22.4% to $2.4350 after the company reported better-than-expected fourth-quarter GAAP EPS results.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) jumped 22.4% to $6.40.</li>
<li>Genprex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>) rose 22.1% to $5.03.</li>
<li>BeyondSpring Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bysi#NASDAQ">BYSI</a>) gained 21% to $3.5098.</li>
<li>Crexendo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxdo#NASDAQ">CXDO</a>) surged 20% to $6.43 following upbeat quarterly results.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) shares gained 17.2% to $348.73 after the company reported better-than-expected fourth-quarter earnings and revenues and issued upbeat guidance for FY25.</li>
<li>Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) rose 17.2% to $12.85.</li>
<li>JD.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jd#NASDAQ">JD</a>) gained 17% to $25.08 after the company reported fourth-quarter results above estimates, a new buyback approval and annual cash dividend.</li>
<li>Hippo Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hipo#NASDAQ">HIPO</a>) rose 14.6% to $16.58 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) rose 13.7% to $44.46.</li>
<li>Super Group (SGHC) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sghc#NYSE">SGHC</a>) surged 10.1% to $3.4350 following fourth-quarter results.</li>
<li>Infinera Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infn#NASDAQ">INFN</a>) gained 10% to $5.66. Infinera announced availability of next generation multi-haul optical line system functionality for industry-leading GX series platform.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 10% to $1,156.87. MicroStrategy shares fell over 21% on Tuesday after the company announced a proposed private offering of $600 million of convertible senior notes.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 9.4% to $18.45.</li>
<li>Couchbase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/base#NASDAQ">BASE</a>) shares rose 9.2% to $29.37 after the company reported upbeat fourth-quarter sales and issued upbeat revenue guidance for the first quarter.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) gained 5.9% to $5.80. On Tuesday, NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Entravision Communications Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evc#NYSE">EVC</a>) shares fell 51.1% to $1.7450 after the company received communication from Meta indicating its intention to wind down its ASP program globally, ending its relationship with all ASPs, including Entravision, by July 1. The ASP program represented a large portion of Entravision&#39;s total consolidated revenue.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) fell 46.4% to $0.20. Neptune announced decision of Nasdaq Hearings Panel to delist common shares.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biaf#NASDAQ">BIAF</a>) fell 45% to $1.6499 after the company announced pricing of a $2.5 million registered direct offering and a concurrent private placement.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) fell 30.5% to $3.6550</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) fell 29% to $0.1272. HeartSciences announced Canada patent grant covering MyoVista Wavelet Technology.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares fell 26.7% to $0.0924 after dipping around 12% on Tuesday.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) dipped 25.8% to $0.0620.</li>
<li>Affimed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) fell 22.3% to $0.52 after the company announced a 1-for-10 reverse stock split.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares fell 21.8% to $11.49. Phunware shares jumped over 18% on Tuesday amid volatility in Trump-related stocks after Donald Trump won the North Dakota Caucus.</li>
<li>PureCycle Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pct#NASDAQ">PCT</a>) dipped 16.7% to $4.71 as the company announced a corporate update for the fourth quarter and fiscal year ending Dec. 31, 2023.</li>
<li>Nordstrom, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jwn#NYSE">JWN</a>) declined 14.6% to $17.83 after the company issued soft FY24 EPS guidance.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares fell 13.2% to $0.6510. Momentus recently received a flight and payload integration services contract from NASA. In another development, Momentus entered into a securities purchase agreement with a single U.S. institutional investor for the purchase and sale of 4.62 million shares of common stock at a purchase price of $0.865 per share and warrant pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.0 million.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) fell 13.1% to $5.36 after declining around 7% on Tuesday.</li>
<li>THOR Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tho#NYSE">THO</a>) dipped 11.4% to $112.19 after the company reported a year-over-year decrease in second-quarter financial results and cut FY24 guidance below estimates.</li>
<li>TTEC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttec#NASDAQ">TTEC</a>) fell 10.2% to $11.16 after Canaccord Genuity downgraded the stock from Buy to Hold and lowered its price target from $30 to $13.</li>
<li>Dave Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dave#NASDAQ">DAVE</a>) fell 10% to $32.40. On Tuesday, Dave reported a year-over-year increase in fourth-quarter revenue results.</li>
<li>Brown-Forman Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bf-b#NYSE">BF-B</a>) fell 9.8% to $54.82 after the company reported worse-than-expected third-quarter revenue guidance. Also, the company expects its FY24 organic net sales to be flat.</li>
<li>SOPHiA GENETICS SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soph#NASDAQ">SOPH</a>) shares declined 9.8% to $5.05. Sophia Genetics recently reported worse than expected fourth-quarter earnings and issued 2024 guidance.</li>
<li>Xerox Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NASDAQ">XRX</a>) fell 9.6% to $16.99 after the company announced a proposed convertible notes offering.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) declined 8.9% to $12.02.</li>
<li>Valley National Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vly#NYSE">VLY</a>) dipped 8.5% to $7.20.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37502729/cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure"> Cramer: This REIT Is &#39;A Little Too Dicey&#39;; As For Marathon Digital, &#39;Own The Pure&#39;</a>

BF-B

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Affimed shares are trading lower after the company announced a 1-for-10 reverse stock split.

The reverse stock split is expected to be effected after market close on March 8, 2024, with the Common Shares expected to begin trading on the Nasdaq Capital Market (&quot;NASDAQ&quot;) on a post-split basis at market open on March 11, 2024 under the Company&#39;s existing trading symbol &quot;AFMD.&quot;

Stock Split

Affimed Announces 1-for-10 Reverse Stock Split

<ul>
<li>Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort</li>
<li>Follow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scan</li>
<li>Study to be expanded to a total of 40 EGFRwt NSCLC patients</li>
<li>Enrollment in the EGFR-mutant (mut) NSCLC cohort is ongoing</li>
<li>Data from both the EGFRwt and EGFRmut cohorts expected in H1 2024 &nbsp;</li>
</ul>
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on the clinical response data for the ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC.
As of January 4, 2024, updated information on the 4 responses in the 15 patients treated in the EGFRwt NSCLC cohort, now show 1 confirmed complete response (CR), 2 confirmed partial responses (PR) and 1 unconfirmed PR awaiting confirmation. Initial data as presented on December 11, 2023, showed 1 confirmed PR as well as 1 unconfirmed CR, and 2 unconfirmed PRs. The patients enrolled in the Phase 1/2a AFM24-102 in the EGFRwt NSCLC cohort of the trial previously had a median of 2 prior lines of therapy, were heavily pretreated, and all patients had progressed on PD-[L]1 targeted therapy.
Based on the promising response data from the EGFRwt NSCLC cohort, Affimed will expand enrollment to 40 patients. Additionally, the Company reported that enrollment of the EGFRmut NSCLC cohort is ongoing. Data from both cohorts are expected in H1 2024.
"We are encouraged by the responses in these patients who had all progressed on PD1 targeting therapy and made the strategic decision to expand this patient cohort," said Dr. Andreas Harstrick, CMO and interim Chief Executive Officer of Affimed. "There is a significant unmet need for these patients who have exhausted all previous lines of therapy and did not respond to any therapies, including PD-1/PD-L1 treatment. We look forward to sharing more updates in the first half of 2024."

Biotech

General

Affimed Provides Clinical Response Update On AFM24-102 Trial In EGFR-Wildtype Non-Small Cell Lung Cancer

Guidance

Affimed Confirms Guidance On Data Readouts For AFM24-102 And  LuminICE-203 In H1 2024

<ul>
<li>Dr. Adi Hoess to step down as CEO and Management Board Member</li>
<li>Dr. Andreas Harstrick appointed Interim CEO</li>
<li>Strategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025</li>
<li>Go forward organization will focus on advancing clinical programs</li>
<li>Company confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024 &nbsp;</li>
</ul>
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- &nbsp;Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
"On behalf of Affimed, I would like to thank Adi for his dedication to the Company. Over the past 13 years, he contributed significantly to the Company's success and guided Affimed's evolution from an antibody engineering company to an innovative late-stage clinical biotech," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "On behalf of Affimed, I wish Adi all the best in his future endeavors."
"Leading Affimed has been an exciting and rewarding journey for me and I am proud of the results achieved - an innovative pipeline of assets for the company and its partners," said Dr. Adi Hoess, Chief Executive Officer. "It has been a privilege to work with the talented and dedicated Affimed team, which shares a strong commitment to deliver meaningful new therapies to patients who need them, and I am confident the Company is well positioned to fulfill its mission."
The Company has initiated a comprehensive search process to identify a successor CEO. In the interim, Dr. Andreas Harstrick, Chief Medical Officer of the Company, will assume the role of interim CEO until a new CEO is appointed. Andreas has nearly 25 years of extensive experience in cancer drug development, including strategic leadership of three global phase 3 programs of new biological entities that culminated in global regulatory approvals, and multiple pivotal phase 3 studies. Given the clinical focus of the company, Andreas is well positioned to lead the company through the transition to a new CEO while continuing as CMO.
Andreas and the management team will be supported by Dr. Annalisa Jenkins, who will ensure close coordination between the Management and Supervisory Boards until a new CEO is appointed. Dr. Jenkins has significant industry experience and has held key leadership positions including CEO of NASDAQ publicly traded company Dimension Therapeutics and head of global research and development at Merck Serono, which make her well-suited for this role.
Strategic Restructuring
Affimed also announced today a restructuring initiative aimed at transforming the Company into a focused clinical organization, positioned to successfully advance its clinical programs to key value inflection points.
Key highlights of the restructuring plan include:
<ul>
<li>Focus on Clinical Programs: Affimed will direct all resources towards advancing the development of its clinical programs. &nbsp;</li>
<li>Workforce reduction: Affimed will reduce its workforce by up to 50% by dissolving its research and preclinical development departments, aligned with the Company's narrowed strategic priorities. &nbsp;</li>
<li>Prolonged Cash Runway: The restructuring plan announced today will extend Affimed's cash runway into H2 of 2025.</li>
</ul>
The Company announced earlier this month the divestiture of AbCheck, the proceeds of which will support ongoing clinical development activities.
The Company confirms guidance related to data readouts in the first half of 2024:
<ul>
<li>Initial data from the LuminICE-203 study of acimtamig in combination with Artiva's NK cell product AlloNK&#xAE; (AB101) in relapsed/refractory Hodgkin's lymphoma.</li>
<li>Data from the AFM24 in combination with atezolizumab in non-small cell lung cancer including initial data readout from the EGFR-mutant cohort and progression free survival from EGFR-wildtype cohort.</li>
</ul>
The Management Board and Supervisory Board of Affimed are confident that these changes are in the best interest of our patients and shareholders and will enable on-going execution of clinical priorities.

Management

Affimed Announces Leadership Change And Organizational Restructuring; Dr. Adi Hoess To Step Down As CEO And Management Board Member; Dr. Andreas Harstrick Appointed Interim CEO; Strategic Restructuring Reducing Headcount By Up To 50%

Shares of Resources Connection, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgp#NASDAQ">RGP</a>) rose sharply in pre-market trading following better-than-expected results for its second quarter.
Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company&rsquo;s quarterly sales came in at $163.1 million versus expectations of $161.936 million.
Resources Connection shares jumped 6.5% to $14.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Jeffs&#39; Brands Ltd(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 60.6% to $5.06 in pre-market trading after surging 25% on Wednesday. Jeffs&#39; Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) rose 41% to $0.1984 in pre-market trading after falling over 11% on Wednesday. Kintara Therapeutics, last month, announced a review of strategic alternatives focused on maximizing stockholder value.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares rose 26.8% to $2.65 in pre-market trading after falling over 9% on Wednesday. Arena Group Board, last month, terminated employment of CEO Ross Levinsohn.</li>
<li>180 Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnf#NASDAQ">ATNF</a>) shares gained 24.4% to $0.2550 in pre-market trading. 180 Life Sciences, last month, engaged financial advisor to explore strategic alternatives.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) shares climbed 10.2% to $0.2259 in pre-market trading after falling over 6% on Wednesday. Advent Technologies recently announced a $2 million registered direct offering of common stock.</li>
<li>BRF S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brfs#NYSE">BRFS</a>) shares rose 9.8% to $2.80 in pre-market trading. JP Morgan analyst Lucas Ferreira, last month, downgraded BRF from Overweight to Neutral.</li>
<li>Affimed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) shares gained 9.3% to $0.6426 in pre-market trading after declining 6% on Wednesday. Affimed announced sale of wholly-owned subsidiary AbCheck for $6 million.</li>
<li>SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) gained 8.7% to $2.13 in pre-market trading after falling 11% on Wednesday.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 8.4% to $4.01 in pre-market trading after falling 8% on Wednesday. Brooge Energy recently reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>SELLAS Life Sciences Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sls#NASDAQ">SLS</a>) shares fell 26.3% to $0.6674 in pre-market trading after announcing a proposed public offering.</li>
<li>Hallmark Financial Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hall#NASDAQ">HALL</a>) shares fell 20.5% to $0.74 in pre-market trading after declining around 25% on Wednesday. Hallmark Financial Services, on Dec. 26, announced that it intends to voluntary delist from the Nasdaq.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares fell 15.3% to $4.62 in pre-market trading. First Wave BioPharma shares jumped 43% on Wednesday after Roth MKM maintained a Buy rating on the stock and adjusted its target from $11 to $40.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) shares fell 15.1% to $1.64 in pre-market trading. ABVC BioPharma shares jumped over 60% on Wednesday after the company and its subsidiary received a milestone payment of 46 million shares from AiBtl BioPharma under a global licensing payment.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) shares fell 14.8% to $1.26 in pre-market trading after dipping 61% on Wednesday.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 13.8% to $1.56 in pre-market trading after surging over 86% on Wednesday.</li>
<li>Evotec SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evo#NASDAQ">EVO</a>) shares fell 11.4% to $9.37 in pre-market trading. Evotec and Owkin announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares fell 10.4% to $0.2631 in pre-market trading after dipping around 35% on Wednesday.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) fell 8.9% to $5.65 in pre-market trading after jumping around 153% on Wednesday.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) fell 5.3% to $51.94 in pre-market trading after the company reported downbeat results for its second quarter.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36484761/walgreens-conagra-brands-and-3-stocks-to-watch-heading-into-thursday"> Walgreens, Conagra Brands And 3 Stocks To Watch Heading Into Thursday</a>

Health Care

Affimed Announces Sale Of Wholly-Owned Subsidiary AbCheck For $6M

Notable earnings before Thursday's open

Affimed GAAP EPS of -€7.09, revenue of €8.28M

Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) just reported results for the fourth quarter of 2023.<ul><li>Affimed reported earnings per share of -$1.50. This was above the analyst estimate for EPS of -$1.67.</li><li>The company reported revenue of $444,549.</li><li>This was 73.85% worse than the analyst estimate for revenue of $1.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/afmd-stock-earnings-affimed-for-q4-of-2023/">AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023

Affimed N.V. (AFMD) said before open Thursday that it broke even in quarter four 2023. In the same quarter a year ago, the company lost $0.22 per share on revenue of $11.4 million. The stock is up 1.59% to $5.42 after the report.Affimed N.V.'s profit margins maintained as both earnings and revenue declined at the same pace

Affimed N.V. Up 1.59% To $5.42 After Earnings

Affimed Therapeutics (AFMD) has released an update. Affimed Therapeutics has reported significant clinical progress in 2023, with promising respons...

Affimed Therapeutics' Optimistic Clinical Outlook

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Affimed (AFMD – Research Report) on March 28 and set a price target of $25.00. Yanan Zhu's...

Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position

Analysts fell to the sidelines weighing in on Affimed (AFMD – Research Report) and Atara Biotherapeutics (ATRA – Research Report) with neutral rati...

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Affimed (AFMD – Research Report), with a price t...

Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Affimed (AFMD – Research Report) today. The company's shares closed last T...

Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)

AGRX

ATRA